The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Oxford BioDynamics proposes GBP7 million fundraise for EpiSwitch plans

Tue, 01st Aug 2023 18:16

(Alliance News) - Oxford BioDynamics PLC on Tuesday said it plans to raise GBP7 million via a placing, subscription and retail offer of new shares in the company.

The Oxford-based biotechnology firm focused on discovering and developing epigenetic biomarkers said it would place a minimum of 43.0 million new shares and direct subscriptions of up to 2.5 million new shares to raise gross proceeds of no less than GBP5 million at an issue price of 11 pence each.

This is alongside a retail offer of new shares to raise up to GBP2 million, also at the issue price. Shares in Oxford BioDynamics closed down 3.3% to 10.40 pence each in London on Tuesday.

Oxford BioDynamics said the fundraising will provide working capital to "support the commercial development, through continued investment in sales and marketing activities to grow adoption of EpiSwitch and spending to complete the validation, launch and initial sales and marketing support of [prostate screening EpiSwitch]".

The fundraising is conditional upon shareholder approval at a general meeting on August 18, among other things.

"We are pleased to announce the proposed fundraising today, securing the group's runway through and beyond the launch of our eagerly awaited prostate screening EpiSwitch test later in 2023. Both existing and new shareholders intend to participate in the fundraising, alongside directors and senior management from across the group," said Chief Executive Officer Jon Burrows.

"We are also pleased that the primary bid offer will enable new and existing retail shareholders to invest in this next exciting phase of OBD's development, on the same terms as institutional investors."

"With the whole OBD team, I look forward to supporting the continued growth of our flagship EpiSwitch CiRT test in the US and UK and working towards a successful commercial launch of the important PSE test to the market."

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
3 Apr 2024 14:31

Oxford BioDynamics reaches "important milestone" with new laboratory

(Alliance News) - Oxford BioDynamics PLC said on Wednesday that it has opened a clinical testing laboratory in the UK to perform EpiSwitch prostate sc...

14 Mar 2024 16:53

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

17 Jan 2024 10:50

CORRECT: Oxford BioDynamics plunges as annual loss widens; revenue up

(Correcting headline to show loss widened, revenue rose)

17 Jan 2024 10:43

CORRECT: Oxford BioDynamics plunge as annual profit rises; revenue up

(Correcting headline to show profit and revenue rose)

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.